168 related articles for article (PubMed ID: 36405755)
1. Identifying tumor antigens and immune subtypes of renal cell carcinoma for immunotherapy development.
Chen X; Zhang T; Zhai X; Wan Z; Ge M; Liu C; Tan M; Xu D
Front Immunol; 2022; 13():1037808. PubMed ID: 36405755
[TBL] [Abstract][Full Text] [Related]
2. Identifying tumor antigens and immune subtypes of gastrointestinal MALT lymphoma for immunotherapy development.
Jiang X; Zhang H; Ni J; Zhang X; Ding K
Front Oncol; 2022; 12():1060496. PubMed ID: 36568181
[TBL] [Abstract][Full Text] [Related]
3. Dissection of tumor antigens and immune landscape in clear cell renal cell carcinoma: Preconditions for development and precision medicine of mRNA vaccine.
Hu J; Mo Z
Math Biosci Eng; 2023 Jan; 20(2):2157-2182. PubMed ID: 36899527
[TBL] [Abstract][Full Text] [Related]
4. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
Huang X; Tang T; Zhang G; Liang T
Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
[TBL] [Abstract][Full Text] [Related]
5. Identification of Tumor Antigens and Immune Subtypes of Esophageal Squamous Cell Carcinoma for mRNA Vaccine Development.
Lu T; Xu R; Wang CH; Zhao JY; Peng B; Wang J; Zhang LY
Front Genet; 2022; 13():853113. PubMed ID: 35734437
[No Abstract] [Full Text] [Related]
6. Tumor antigens and immune subtypes guided mRNA vaccine development for kidney renal clear cell carcinoma.
Xu H; Zheng X; Zhang S; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):159. PubMed ID: 34872567
[TBL] [Abstract][Full Text] [Related]
7. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
Front Immunol; 2021; 12():709986. PubMed ID: 34512630
[TBL] [Abstract][Full Text] [Related]
8. Identification of neoantigens and immunological subtypes in clear cell renal cell carcinoma for mRNA vaccine development and patient selection.
Zhu D; Yang J; Zhang M; Han Z; Shao M; Fan Q; Ma Y; Xie D; Xiao W
Aging (Albany NY); 2023 Jun; 15(11):5190-5214. PubMed ID: 37315301
[TBL] [Abstract][Full Text] [Related]
9. Recognition of Tumor-Associated Antigens and Immune Subtypes in Glioma for mRNA Vaccine Development.
Ma S; Ba Y; Ji H; Wang F; Du J; Hu S
Front Immunol; 2021; 12():738435. PubMed ID: 34603319
[TBL] [Abstract][Full Text] [Related]
10. LRP2 and DOCK8 Are Potential Antigens for mRNA Vaccine Development in Immunologically 'Cold' KIRC Tumours.
Zhang S; Xia K; Chang Y; Wei Y; Xiong Y; Tang F; Peng J; Ouyang Y
Vaccines (Basel); 2023 Feb; 11(2):. PubMed ID: 36851274
[TBL] [Abstract][Full Text] [Related]
11. A promising Prognostic risk model for advanced renal cell carcinoma (RCC) with immune-related genes.
Cao P; Wu JY; Zhang JD; Sun ZJ; Zheng X; Yu BZ; Cao HY; Zhang FL; Gao ZH; Wang W
BMC Cancer; 2022 Jun; 22(1):691. PubMed ID: 35739510
[TBL] [Abstract][Full Text] [Related]
12. Identification of Tumor Antigens and Immune Subtypes of Glioblastoma for mRNA Vaccine Development.
Lin H; Wang K; Xiong Y; Zhou L; Yang Y; Chen S; Xu P; Zhou Y; Mao R; Lv G; Wang P; Zhou D
Front Immunol; 2022; 13():773264. PubMed ID: 35185876
[TBL] [Abstract][Full Text] [Related]
13. Identification of tumor-antigen signatures and immune subtypes for messenger RNA vaccine selection in advanced clear cell renal cell carcinoma.
Xu Z; Wu Y; Chen X; Jin B
Surgery; 2024 Jun; ():. PubMed ID: 38851900
[TBL] [Abstract][Full Text] [Related]
14. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.
Ping H; Yu W; Gong X; Tong X; Lin C; Chen Z; Cai C; Guo K; Ke H
Invest New Drugs; 2022 Dec; 40(6):1173-1184. PubMed ID: 35962880
[TBL] [Abstract][Full Text] [Related]
15. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
[TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of tumor antigens in hepatocellular carcinoma for mRNA vaccine development.
Fu J; Chen F; Lin Y; Gao J; Chen A; Yang J
J Cancer Res Clin Oncol; 2023 Jul; 149(7):4047-4061. PubMed ID: 36038676
[TBL] [Abstract][Full Text] [Related]
17. Immune Cell Infiltration and Identifying Genes of Prognostic Value in the Papillary Renal Cell Carcinoma Microenvironment by Bioinformatics Analysis.
Liu T; Zhang M; Sun D
Biomed Res Int; 2020; 2020():5019746. PubMed ID: 32775427
[TBL] [Abstract][Full Text] [Related]
18. Identification of Five Tumor Antigens for Development and Two Immune Subtypes for Personalized Medicine of mRNA Vaccines in Papillary Renal Cell Carcinoma.
Hu J; Yuan Z; Jiang Y; Mo Z
J Pers Med; 2023 Feb; 13(2):. PubMed ID: 36836593
[TBL] [Abstract][Full Text] [Related]
19. Regulation of carcinoma cell invasion by protein C inhibitor whose expression is decreased in renal cell carcinoma.
Wakita T; Hayashi T; Nishioka J; Tamaru H; Akita N; Asanuma K; Kamada H; Gabazza EC; Ido M; Kawamura J; Suzuki K
Int J Cancer; 2004 Feb; 108(4):516-23. PubMed ID: 14696115
[TBL] [Abstract][Full Text] [Related]
20. Long noncoding RNA EGFR-AS1 promotes cell growth and metastasis via affecting HuR mediated mRNA stability of EGFR in renal cancer.
Wang A; Bao Y; Wu Z; Zhao T; Wang D; Shi J; Liu B; Sun S; Yang F; Wang L; Qu L
Cell Death Dis; 2019 Feb; 10(3):154. PubMed ID: 30770799
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
